Sacubitril/valsartan attenuates atrial structural remodelling in atrial fibrillation patients
Abstract Aims Radiofrequency catheter ablation (RFCA) is now an established therapeutic option for patients with atrial fibrillation (AF), but the long‐term recurrence rate of AF is still high. Sacubitril/valsartan (Sac/Val) is superior to valsartan in attenuating ventricular remodelling and improvi...
Gardado en:
| Principais autores: | , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Oxford University Press
2022-08-01
|
| Series: | ESC Heart Failure |
| Assuntos: | |
| Acceso en liña: | https://doi.org/10.1002/ehf2.13937 |
| Tags: |
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|